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Polymorphisms and Promoter Overactivity of the p22phox
Gene in Vascular Smooth Muscle Cells From Spontaneously
Hypertensive Rats
Guillermo Zalba, Gorka San José, Francisco J. Beaumont, María A. Fortuño, Ana Fortuño, Javier Díez
Abstract—In a previous study, we found that the p22phox subunit of the NADH/NADPH oxidase is overexpressed in
vascular smooth muscle cells (VSMCs) from spontaneously hypertensive rats (SHRs) with enhanced vascular
production of superoxide anion (·O22). Thus, we have investigated whether changes in the sequence or activity of the
promoter region of p22phox gene are present in SHRs. To carry out this analysis, first of all, we characterized the rat gene
structure and promoter region for the p22phox subunit. The p22phox gene spans ’10 kb and contains 6 exons and 5 introns.
Primer extension analysis indicated the transcriptional start site 100 bp upstream from the translational start site. The
immediate promoter region of the p22phox gene does not contain a TATA box, but there are a CCAC box and putative
recognition sites for nuclear factors, such as SP1, g-interferon, and nuclear factor-kB. Using reporter-gene transfection
analysis, we found that this promoter was functional in VSMCs. Furthermore, we observed that p22phox promoter activity
was significantly higher in VSMCs from SHRs than from normotensive Wistar-Kyoto rats. In addition, we found that
there were 5 polymorphisms in the sequence of p22phox promoter between Wistar-Kyoto rats and SHRs and that they
were functional. The results obtained in this study provide a tool to explore the mechanisms that regulate the expression
of p22phox gene in rat VSMCs. Furthermore, our findings show that changes in the sequence of p22phox gene promoter
and in the degree of activation of VSMCs are responsible for upregulated expression of p22phox in SHRs. (Circ Res.
2001;88:217-222.)
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Oxidative stress induced by vascular superoxide anion(·O22) has been implicated in the development of hyper-
tension1–3 and atherosclerosis.4,5 The enzyme NADH/
NADPH oxidase plays a major role as the most important
source of superoxide anion in the vessel wall.6–9 Although
vascular NADH/NADPH is similar to the neutrophil NADPH
oxidase, recent studies suggest that it represents a novel
family of oxidative enzymes.10 Recent investigations show
that p22phox, a component of the NADH/NADPH oxidase, is
expressed in vascular smooth muscle cells (VSMCs) and
plays an essential role in ·O22 generation in these cells.11
Recently, we reported that enhanced NADH/NADPH oxi-
dase–driven ·O22 production in the aorta of adult spontane-
ously hypertensive rats (SHRs) was associated with upregu-
lation of p22phox mRNA.12 Our data pointed to VSMCs as the
potential source for both p22phox mRNA overexpression and
·O22 overproduction in the aorta of SHRs. Thus, we hypoth-
esized that p22phox mRNA upregulation observed in VSMCs
from SHRs could be a consequence of either modifications in
the p22phox gene-promoter sequence or differences in its
activation degree. Thus, the first goal of this study was to
perform the structural and functional characterization of rat
p22phox gene. Second, we compared the p22phox promoter
sequences from normotensive Wistar-Kyoto (WKY) rats and
SHRs. Finally, we analyzed the p22phox promoter activity in
VSMCs from the 2 strains of rats.
Materials and Methods
Exon Mapping
Rat genomic DNA was isolated from peripheral blood leukocytes by
standard methods. The intron positions were determined by poly-
merase chain reaction (PCR) amplification of rat genomic DNA
using oligonucleotides on the basis of rat p22phox cDNA sequence
(p1: 59-GGCAGATCGAGTGGGCCATGTG-39; p2: 59-AGGTA-
GATCACACTGGCAATG-39; p3: 59-CATTGCCAGTGTGAT-
CTACCTG-39; p4: 59-GCTTGATGGTGCCTCCAACCTG-39). The
resultant products were cloned into pCR (Invitrogen) and sequenced.
Cloning of the 5*-Flanking Region
The 59-flanking region of the gene was amplified using the Promoter
Finder System from Clontech. This kit contains pools of uncloned,
adaptor-ligated genomic DNA fragments. A first amplification was
performed between an outer adapter primer (ap1, 59-
GTAATACGACTCACTATAGGGC-39) and a p22phox cDNA-
specific primer (sp1, 59-GCCAGATGCCAGCGCCTGTTCGTTG-
39). A second round of PCR was done using the nested adaptor
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primer (ap2, 59-ACTATAGGGCACGCGTGGT-39) and a nested
p22phox-specific primer (sp2, 59-TGGCCCACATGGCCCACTCGA-
TCTG-39). The amplifications were carried out according to the
supplier’s protocol. The two rat p22phox cDNA-specific primers were
localized in the exon 1. This protocol detected a single clear band.
This band was ’2.5 kbp and was subcloned into pCR plasmid for
additional sequencing reactions.
For comparing experiments between WKY and SHR p22phox
promoter sequences, the 2500-bp fragment corresponding to p22phox
full promoter was amplified using Pfu polymerase from WKY and
from SHR genomic DNA cloned into pCR plasmid and sequenced.
Primer Extension Analysis
Primer extension was carried out using the antisense oligonucleotide
PE1 (59-GCCGGACGCCTGCGCCTGCTCGTTG-39), correspond-
ing to a sequence located in exon 1. The oligonucleotide was
end-labeled with [g32P]ATP, hybridized to 5 mg of mRNA extracted
from the rat kidney, and extended using Moloney murine leukemia
virus reverse transcriptase. The primer-extended product was sepa-
rated on a 7 mol/L urea 6% polyacrylamide gel, dried, and exposed
to generate the corresponding autoradiography.
Plasmid Construction
A 2.5-kb fragment containing the p22phox 59-untranslated region and
including the codon ATG of exon 1 was cloned in pCR. Serial
deletion fragments from the p22phox promoter were generated by PCR
using Pfu polymerase and 7 nested sense primers. Sense and
antisense primers were designed for containing HindIII restriction
sites. After digestion with HindIII, products were cloned into
HindIII-digested pGL3 basic (Promega). Insert orientation was
controlled by sequencing of the fusion sites.
To compare the p22phox promoter activity between WKY and SHR
sequences, the 2500-bp fragments corresponding to the WKY and
SHR p22phox full promoters were cloned in pGL3 basic plasmid.
Cell Culture
Primary VSMCs were obtained from the thoracic aorta and cultured
as previously reported.13 VSMCs were cultured in DMEM with 10%
FCS. The rat aortic smooth muscle cell line A7r5 was cultured in
DMEM with 10% FCS supplemented with sodium pyruvate. Cells
were incubated at 37°C in a humidified atmosphere of 5% CO2 in air.
For studies with VSMCs from WKY rats and SHRs, cells were
obtained from the aortas of 30-week-old SHRs and WKY rats.
Transfection Experiments and Luciferase Activity
A7r5 cells (2.53105 cells) and VSMCs (53105 cells) were plated 24
hours before transfection into 60-mm tissue-culture dishes. Transient
transfection was performed by Superfect method (Qiagen) with 2 mg
of luciferase construct and 40 ng of pRL-SV40 (Promega). DNA/
superfect ratio was 1:7.5 (wt/wt). Cells were maintained in the
presence of this mixture for 3 hours and then washed, and the assays
for luciferase activity were performed 24 hours later using a
dual-luciferase reporter assay system (Promega). Luciferase activity
was expressed in arbitrary light units per microgram of cellular
protein. As controls, pGL3 basic and pGL3 promoter (Promega)
were transfected in parallel experiments.
Results
Genomic Organization of the Rat p22phox Gene
The positions of introns within the rat p22phox gene were
mapped by PCR amplification of rat genomic DNA using
oligonucleotides derived from the rat cDNA sequence. The
p22phox gene is ’10 kbp in length and is composed of 6 exons
and 5 introns (Figure 1). Exon size ranges between 70 bp
(exon 2) and 296 bp (exon 6). Introns, which are flanked by
typical splice donor and acceptor sequences, range between
400 bp (intron 2) and 4.8 kb (intron 1) (Table 1).
Inspection of the sequence of the 59-flanking region indi-
cated that although there was not typical TATA box in close
proximity to the transcriptional start site, there was a CCAC
box. Furthermore, there were multiple transcription factor
binding sites, such as SP1, AP1, AP4, GATA, g-interferon,
and nuclear factor-kB (NF-kB) (Figure 2), that might tran-
scriptionally regulate p22phox gene expression. A primer ex-
tension experiment was performed with an antisense oligo-
nucleotide that mapped in the first exon close to the
translation initiation codon ATG. The results clearly indicate
the existence of a predominant site for transcription initiation,
pointed to a C located 100 nucleotides upstream of the codon
ATG.
Promoter Function of the p22phox Gene
To determine whether the putative promoter region is func-
tional, a 2500-bp fragment containing the complete promoter
was subcloned into a luciferase reporter plasmid (p22c1)
(Figure 3) and transfected into A7r5 cells and VSMCs. As
shown in Figure 4A, remarkable expression was observed in
both types of cells. Relative expression of p22c1 to that of the
pGL3 promoter was higher (P,0.05, Student’s unpaired t
test) in A7r5 cells than in VSMCs.
To define the regions required for promoter activity, we
cloned a series of progressively deleted DNA fragments of
the putative promoter directly upstream of the firefly lucif-
erase reporter gene (Figure 3). The resulting plasmids were
transiently expressed in A7r5 cells. As shown in Figure 4B,
constructs p22c6 and p22c7 produced relatively strongest
signals. This identified positive regulatory elements involved
in basal promoter activity in the proximal part of the p22phox
promoter between 2402 bp and 11 bp, such as AP1, AP4,
GAGA, and NF-kB.
Figure 1. A, Organization of the rat p22phox gene. Boxes denote
exons, and lines denote introns and 59-flanking region. B,
Genomic PCR products obtained with the pair of primers p1/p2,
p3/p4, and sp2/ap2. ap2 primer is an adapter-specific primer
used for amplification of p22phox promoter from adaptor-ligated
genomic DNA fragments by using the Promoter Finder System.
TABLE 1. Exon-Intron Organization of the Rat p22phox Gene
Exon Intron Exon
TGGCCTGA gtgagtgaagtg (intron 1, ’4800 bp) caccctccatctttag TCCTCATC
TACTCTAT gtatccttctac (intron 2, ’390 bp) ttccttaccctcacctcag TGTTGCAG
GAGCGGTG gtaagtcactcc (intron 3, ’190 bp) ttgtcttcccgctgtctag TGGACAGA
CACTTACT gtgtgagtct (intron 4, ’800 bp) ttcctcctgtcatacctcaag GCTGTCCG
ACCTGCTG gtaagtggatgt (intron 5, ’1100 bp) ttctctgacccag GCAGCCAT
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p22phox Promoter Activity in VSMCs from WKY
Rats and SHRs
To determine whether the upregulation of p22phox gene ex-
pression is dependent of the level of cell activation, the full
promoter (construct p22c1) was transfected into VSMCs
from WKY rats and SHRs. As shown in Figure 5, relative
expression of p22c1 to that of the pGL3 promoter was 2-fold
higher (P,0.05) in cells from SHRs than in cells from WKY
rats.
To determine the functional significance of putative bind-
ing sites for NF-kB transcription factor, we performed exper-
iments to know whether deletion of the NF-kB sites abro-
gated the difference in promoter activity observed between
WKY and SHR VSMCs. Transfection experiments were
Figure 2. Nucleotide sequence of the rat p22phox gene promoter. Several consensus sites for transcriptional factors are underlined.
SREBP1 indicates sterol regulatory element-binding protein 1; RREB1, ras-responsive element binding protein 1. Nucleotide number
was counted from the transcriptional start site (11), indicated by the arrowhead (). Arrows indicate the 59 end of the deletion mutants
for p22phox promoters shown in Figure 3. The nucleotide sequence has been submitted to the GenBank databank with accession num-
ber AF279334.
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performed with construct p22c7, without these NF-kB sites,
on VSMCs from WKY rats and SHRs. As shown in Figure 5,
deletion of NF-kB does not abrogate the difference in
promoter activity observed between SHR and WKY VSMCs.
p22phox Promoter Sequences in WKY Rats
and SHRs
To determine whether the upregulation of p22phox gene ex-
pression in SHRs was the consequence of differences in the
p22phox promoter sequence, a 2500-bp fragment corresponding
to the p22phox full promoter was amplified from WKY rats and
SHR genomic DNA and sequenced as described above. The
comparison of the WKY rats and SHR p22phox promoters by a
computer analysis revealed that the sequence of the WKY
promoter does not match completely the SHR promoter
sequence. In fact, we found 5 polymorphisms: 4 in the
upstream region of the gene at positions 21628, 2218,
2166, and 214 from the first transcribed nucleotide and 1 in
the nontranslated region at position 142 (Table 2).
To test whether there is any functional significance to the
promoter polymorphisms, transfection experiments on A7r5
cells and on VSMCs from WKY rats and SHRs were
performed with the WKY full promoter and with the SHR full
promoter. As shown in Figure 6, the activity of the SHR
polymorphic construct was higher (P,0.05, Student’s t test)
than the activity of WKY construct in all cell types.
Discussion
In the present study, we established the genomic structure of
the rat p22phox gene, which contains 6 exons and 5 introns and
spans a region of 10 kb. We found that the rat exon-intron
genomic structure is very similar to that of the human p22phox
gene.14 In addition, this is the first study that characterizes the
promoter region of a p22phox gene. The p22phox promoter
possesses no typical TATA in the appropriate positions, but
there is a CCAC box. Furthermore, sequence analysis of the
p22phox promoter region revealed several potential consensus
sequences for transcriptional factors.
p22phox is a common component of vascular and phagocytic
NADH/NADPH oxidases.10 Despite their similarities, vascu-
lar and phagocytic NADH/NADPH oxidases posses enzy-
matic differences. Thus, the vascular oxidase system prefers
NADH to NADPH as substrate for its activity and has much
lower activity in contrast to phagocytic oxidase. Recent
Figure 3. Deletion mutants of the rat p22phox promoter-luciferase
constructs.
Figure 4. Analysis of the rat p22phox gene promoter. A, Transfec-
tion experiments with p22c1 into A7r5 cells and VSMCs. Data
are expressed as relative luciferase activity (arbitrary light units
per mg protein of the p22phox promoter of that of the pRL-SV40
promoter). Values are mean6SE of 5 determinations. *P,0.05
compared with VSMCs, determined by Student’s t test. B, A7r5
cells were transiently transfected with the indicated plasmids,
and luciferase activity was measured. Values are mean6SE of 5
determinations.
Figure 5. Histograms showing the results from transfection
experiments with p22c1 and p22c7 into VSMCs from WKY rats
and SHRs. Data are expressed as relative luciferase activity
(arbitrary light units per mg protein of the p22phox promoter of
that of the pRL-SV40 promoter). Values are mean6SE of 10
determinations. *P,0.05 compared with WKY rats, determined
by Student’s t test.
TABLE 2. Variants Identified in the p22phox Gene
Location Position Substitution WKY3SHR
59 21628 C3T
59 2218 C3T
59 2166 A3G
59 214 C3T
59 142 A3G
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studies have reported the significance of p22phox overexpres-
sion gene in cardiovascular diseases. Vascular p22phox is
expressed at low levels in normal vessels and is upregulated
in atherosclerosis4,15 and hypertension9,12 and in response to
trophic factors, such as angiotensin II,16 and cytokines, such
as tumor necrosis factor-a.17
From previous findings, we proposed a significant role for
upregulation of VSMC p22phox mRNA in NADH/NADPH-
driven ·O22 overproduction found in the aorta from adult
SHRs.12 A possible origin of p22phox upregulation would be
some difference in the p22phox promoter sequence. We iden-
tified 5 polymorphisms in the 59 region of the p22phox gene, 1
polymorphisms located in nontranslated region (142), and 4
polymorphisms located in the promoter region (214, 2166,
2218, and 21628 bp). Interestingly, we have found that
these polymorphisms possess functional significance, sug-
gesting that they may be involved in overexpression of the
p22phox gene. This is additionally reinforced by the observa-
tion that 4 of these 5 polymorphisms are situated in the first
250 bp, where it seems that maximal basal promoter activity
of the p22phox gene is localized.
Another finding of this study is that p22phox promoter
activity was higher in VSMCs from SHRs compared with
VSMCs from WKY rats, suggesting that in vivo variations in
the expression of the p22phox gene might be the result of
differences in the level of activation of cells from the 2 strains
of rats.18,19 For instance, stimulation of VSMCs from SHRs
with angiotensin II20 results in an amplified activation of
transduction pathways. In addition, exaggerated production
of angiotensin II and enhanced expression of both AT1
receptor and angiotensin-converting enzyme21 have been
reported in vessels of SHRs compared with WKY rats. Thus,
the possibility exists that angiotensin II can be involved in
changes in cell activation that, in turn, influence the expres-
sion of p22phox gene in SHR VSMCs. Although additional
studies are necessary to test this hypothesis, some arguments
are in accordance with it. First, angiotensin II has been found
to stimulate p22phox expression and NAD(P)H-driven ·O22
production in the rat aorta.16 This effect was inhibited by
treatment with losartan, suggesting that it was mediated by
the interaction of angiotensin II with AT1 receptors. Second,
we reported previously that chronic blockade of AT1 recep-
tors with irbesartan decreased p22phox expression and ·O22
production in the aorta of SHR despite a noncomplete
normalization of blood pressure.12
It has been shown recently that angiotensin II activates
NF-kB in VSMCs.22 Furthermore, NF-kB has been impli-
cated in the transcription of several vascular genes.23,24
Nevertheless, from our data with p22c7 construct, it is unlike
that upregulated p22phox expression seen in VSMCs from
SHRs is mediated by a NF-kB–dependent pathway. In fact,
experiments on luciferase activity with the deleted promoter
construct show that deletion of NF-kB sites does not abrogate
the difference in p22phox promoter activity between SHR and
WKY VSMCs (Figure 5). Similarly, it is unlikely that other
sites (ie, AP1 and AP4) also absent in the p22c7 construct are
important for the observed differences. In contrast, the GATA
and MZF1 sites are more likely to mediate promoter activity,
because they are retained in p22c7.
In summary, we have characterized the genomic structure
of the rat p22phox gene promoter, providing a tool to explore
the mechanisms regulating the expression of this gene in
VSMCs. Our results suggest that besides changes in activa-
tion degree of VSMCs associated with the development of
hypertension in SHRs, the presence of several polymor-
phisms in the promoter region of the p22phox gene may
contribute to enhanced p22phox promoter activity in SHRs.
Thus, the findings reported here provide a potential explana-
tion for the upregulation of p22phox in the vessel wall of SHRs.
The significance of these experimental results is underlined
by clinical data, indicating the occurrence of increased ·O22
production in humans with essential hypertension25,26 and the
existence of an association between a p22phox gene polymor-
phism and NAD(P)H oxidase–mediated ·O22 production in
the vascular wall of patients with atherosclerosis.27
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